These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 8071711)
21. Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle. Sgouros G J Nucl Med; 1995 Oct; 36(10):1910-2. PubMed ID: 7562063 [No Abstract] [Full Text] [Related]
22. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878 [TBL] [Abstract][Full Text] [Related]
23. Principles of radioimmunotherapy for hematologists and oncologists. Press OW; Rasey J Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002 [TBL] [Abstract][Full Text] [Related]
24. [The determination of the optimal irradiation dose in the tumor tissue-normal body tissues system]. Klepper LIa Med Tekh; 1997; (4):18-21. PubMed ID: 9379858 [TBL] [Abstract][Full Text] [Related]
25. TCP and NTCP: a basic introduction. Baumann M; Petersen C Rays; 2005; 30(2):99-104. PubMed ID: 16294901 [TBL] [Abstract][Full Text] [Related]
26. How far have we come with solid (nonhematologic) tumor radioimmunotherapy? Breitz HB J Nucl Med; 2000 Dec; 41(12):2011-4. PubMed ID: 11138686 [No Abstract] [Full Text] [Related]
27. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo. Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571 [TBL] [Abstract][Full Text] [Related]
28. Determination of biological vector characteristics and nanoparticle dimensions for radioimmunotherapy with radioactive nanoparticles. Nuttens VE; Wéra AC; Bouchat V; Lucas S Appl Radiat Isot; 2008 Feb; 66(2):168-72. PubMed ID: 17913502 [TBL] [Abstract][Full Text] [Related]
29. [Value of multiple daily doses in radiotherapy: hyperfractionation]. Girinsky T; Cosset JM; Malaise EP Rev Prat; 1990 Mar; 40(8):735-7. PubMed ID: 2320899 [No Abstract] [Full Text] [Related]
30. Optimization of radiotherapy using biological parameters. Kim Y; Tomé W Cancer Treat Res; 2008; 139():257-78. PubMed ID: 18236720 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer. Juweid M; Sharkey RM; Swayne LC; Griffiths GL; Dunn R; Goldenberg DM J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735 [TBL] [Abstract][Full Text] [Related]
32. Mathematical models of cumulative effect and optimization of fractionation regimes. Judas L; Lokajícek M; Prokes K Strahlenther Onkol; 1988 Feb; 164(2):111-6. PubMed ID: 3344478 [TBL] [Abstract][Full Text] [Related]